NO20045249L - Epotilonderivat for behandling av hepatom og andre kreftsykdommer - Google Patents

Epotilonderivat for behandling av hepatom og andre kreftsykdommer

Info

Publication number
NO20045249L
NO20045249L NO20045249A NO20045249A NO20045249L NO 20045249 L NO20045249 L NO 20045249L NO 20045249 A NO20045249 A NO 20045249A NO 20045249 A NO20045249 A NO 20045249A NO 20045249 L NO20045249 L NO 20045249L
Authority
NO
Norway
Prior art keywords
treatment
progressing
radiotherapy
cancer
hepatoma
Prior art date
Application number
NO20045249A
Other languages
English (en)
Norwegian (no)
Inventor
John David Rothermel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20045249L publication Critical patent/NO20045249L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Silicon Polymers (AREA)
NO20045249A 2002-05-01 2004-11-30 Epotilonderivat for behandling av hepatom og andre kreftsykdommer NO20045249L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37706302P 2002-05-01 2002-05-01
PCT/EP2003/004581 WO2003092683A1 (en) 2002-05-01 2003-04-30 Epothilone derivative for the treatment of hepatoma and other cancer diseases

Publications (1)

Publication Number Publication Date
NO20045249L true NO20045249L (no) 2005-01-26

Family

ID=29401440

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045249A NO20045249L (no) 2002-05-01 2004-11-30 Epotilonderivat for behandling av hepatom og andre kreftsykdommer

Country Status (23)

Country Link
US (2) US20050282873A1 (de)
EP (1) EP1503756B1 (de)
JP (1) JP2005528414A (de)
KR (1) KR20040106422A (de)
CN (1) CN1649585A (de)
AT (1) ATE439130T1 (de)
AU (1) AU2003227702B2 (de)
BR (1) BR0309711A (de)
CA (1) CA2483826C (de)
CY (1) CY1109607T1 (de)
DE (1) DE60328772D1 (de)
DK (1) DK1503756T3 (de)
ES (1) ES2330324T3 (de)
IL (1) IL164783A (de)
MX (1) MXPA04010853A (de)
NO (1) NO20045249L (de)
NZ (1) NZ536178A (de)
PL (1) PL211114B1 (de)
PT (1) PT1503756E (de)
RU (1) RU2358730C2 (de)
SI (1) SI1503756T1 (de)
WO (1) WO2003092683A1 (de)
ZA (1) ZA200408492B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1649585A (zh) * 2002-05-01 2005-08-03 诺瓦提斯公司 用于治疗肝脏肿瘤和其它癌症疾病的埃坡霉素衍生物
US20060235059A1 (en) * 2003-09-02 2006-10-19 Dilea Clifford Cancer treatment with epothilones
US8394365B2 (en) 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
EP1640004A1 (de) * 2004-09-24 2006-03-29 Schering Aktiengesellschaft Verwendung von Epothilonen zur Behandlung von Knochenmetastasen und Knochentumoren oder Knochenkrebs
EP1824458A1 (de) * 2004-11-18 2007-08-29 Bristol-Myers Squibb Company Kügelchen mit magensaftresistentem überzug mit epothilon oder einem epothilon-analogon und seine herstellung und verabreichung
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
JP2008536479A (ja) 2005-02-11 2008-09-11 ユニバーシティ オブ サザン カリフォルニア ジスルフィド架橋を有するタンパク質の発現法
US8008256B2 (en) 2006-05-01 2011-08-30 University Of Southern California Combination therapy for treatment of cancer
MX2008004267A (es) * 2008-03-28 2009-09-28 Posi Visionary Solutions Llp Metoclopramida de liberacion prolongada de 12 horas.
MX2008004268A (es) * 2008-03-28 2009-09-28 Posi Visionary Solutions Llp Metoclopramida de liberacion prolongada de 24 horas.
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
CN101747326B (zh) * 2010-01-12 2012-07-25 山东大学 18元大环内酯类埃博霉素化合物及其应用
CN103037903A (zh) 2010-05-18 2013-04-10 天蓝制药公司 用于治疗自身免疫性疾病或其它疾病的组合物和方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6660758B1 (en) * 1996-12-13 2003-12-09 The Scripps Research Institute Epothilone analogs
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
WO2000050423A1 (en) * 1999-02-22 2000-08-31 Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) C-21 modified epothilones
GB9918429D0 (en) * 1999-08-04 1999-10-06 Novartis Ag Organic compounds
CN1649585A (zh) * 2002-05-01 2005-08-03 诺瓦提斯公司 用于治疗肝脏肿瘤和其它癌症疾病的埃坡霉素衍生物

Also Published As

Publication number Publication date
JP2005528414A (ja) 2005-09-22
AU2003227702B2 (en) 2007-07-26
PL371727A1 (en) 2005-06-27
ES2330324T3 (es) 2009-12-09
AU2003227702A1 (en) 2003-11-17
CA2483826C (en) 2012-04-17
PL211114B1 (pl) 2012-04-30
NZ536178A (en) 2007-10-26
HK1073601A1 (en) 2005-10-14
RU2004135307A (ru) 2005-09-10
PT1503756E (pt) 2009-10-28
IL164783A (en) 2011-08-31
RU2358730C2 (ru) 2009-06-20
EP1503756A1 (de) 2005-02-09
MXPA04010853A (es) 2005-02-14
CA2483826A1 (en) 2003-11-13
DK1503756T3 (da) 2009-11-16
BR0309711A (pt) 2005-02-09
EP1503756B1 (de) 2009-08-12
US20080161369A1 (en) 2008-07-03
ZA200408492B (en) 2006-09-27
US20050282873A1 (en) 2005-12-22
CN1649585A (zh) 2005-08-03
IL164783A0 (en) 2005-12-18
CY1109607T1 (el) 2014-08-13
DE60328772D1 (de) 2009-09-24
SI1503756T1 (sl) 2010-01-29
WO2003092683A1 (en) 2003-11-13
ATE439130T1 (de) 2009-08-15
KR20040106422A (ko) 2004-12-17

Similar Documents

Publication Publication Date Title
CY1109607T1 (el) Παραγωγο εποθιλονης για τη θεραπευτικη αντιμετωπιση του ηπατωματος και αλλων κακοηθων νοσων
PH12019502586A1 (en) N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof
EA201201154A1 (ru) Ингибиторы фосфатидилинозит-3-киназы и способы их применения
NO2017019I1 (no) Diarylhydantoinforbindelse, farmasøytisk sammensetning og anvendelse derav
NZ580009A (en) Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
RU2012140185A (ru) Ингибирование ангиогенеза
MX2011012584A (es) Benzoxazepinas como inhibidores de pi3k/m tor, metodos para su uso y fabricación.
EA201290062A1 (ru) Соединения, связывающие белки теплового шока, композиции и способы получения указанных соединений
EA200970317A1 (ru) Комбинированное лечение опухолей, экспрессирующих cd38
NO20044475L (no) 2-(2,6-diklorfenyl)-diarulimidazoler
RU2018102963A (ru) Производные анилинпиримидина и их применения
DK1896507T3 (da) Anti-CD71-monoklonale antistoffer og anvendelser deraf til behandling af maligne tumorceller
ATE461713T1 (de) Zusammensetzungen für die radioimmuntherapie von gehirn-tumoren
DE602005015304D1 (de) Krebstherapie mit einem nukleären rezeptorliganden und einem hdac-hemmer
JP2022537453A5 (de)
JP2023517671A5 (de)
MX2024005434A (es) Inhibidores de ddr1 y ddr2 para el tratamiento de cancer y enfermedades fibroticas.
EA200970949A1 (ru) Способы лечения неоплазии при помощи комбинации химиотерапевтических агентов и облучения
TW200732305A (en) Cancer chemotherapy
DE602004014965D1 (de) Bisindolylmaleimid zur behandlung von prostatakrebs und akt-vermittelten erkrankungen
ATE406375T1 (de) Antitumor wirksame 2-substituierte d-homoestra-1, 3,5(10)-trien-3-yl sulfamate
NO20055650D0 (no) Ruteinum (II)-komplekser for behandling av tumorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application